Mette Hammer

Mette Hammer has extensive work experience in the biotech and pharmaceutical industry. Mette started their career at LEO Pharma A/S as a Group Pharmacoeconomist from 1998 to 2005. Mette then joined Novo Nordisk in 2005 and held various roles such as Senior Health Economist, Associate Director, Victoza Market Access, Associate Director for GLP-1 pipeline and Obesity, Director of HEOR for GLP-1, Global Market Access Director (HEOR/RWE), and Global Senior Director of Global Patient Access. Their responsibilities at Novo Nordisk included leading teams in health economics, real-world evidence, and market access to optimize patient access and support market access throughout the brands' lifecycle.

In 2020, Mette Hammer joined Zealand Pharma as a Senior Director, Head of HEOR & RWE, Global Medical Affairs. Mette was responsible for leading a team in RWE & HEOR globally and the US field HEOR team. Their role focused on diabetes and rare diseases, specifically Congenital Hyperinsulinism (CHI) and Short Bowel Syndrome (SBS). Later in 2022, they became the Senior Director and Head of Medical Affairs at Zealand Pharma, where they provided leadership in Biotech Medical Affairs with a focus on diabetes, obesity, and rare diseases, including CHI and SBS. Currently, they hold the position of Senior Project Director at Zealand Pharma.

Mette Hammer completed their Msc. Econ in Health Economics at the University of Copenhagen from 1990 to 1996. Later, from 1999 to 2000, they earned a Diploma of Basic Pharmaceutical Medicine from the Danish Association of Pharmaceutical Industries, focusing on Medicines.